Purpose: The recent expansion of electronic health and medical record systems may present an opportunity to generate robust post-approval safety data and obviate the limitations of prospective pregnancy exposure registries. We examined and compared, over the same time frame, the outcomes of triptan exposure in pregnancy using (1) a retrospective claims database and (2) a previously completed pregnancy registry.
| INTRODUCTION
While pregnant women are generally excluded from pivotal clinical trials that generate efficacy and safety data supporting approval of new medications, they may be exposed to these agents once they are approved and marketed. 1 Thus, regulatory authorities have typically required post-approval safety studies in pregnant women if exposures to the medical product in pregnancy are expected to be common. In the United States, the Food and Drug Administration requires industry sponsors to conduct these pregnancy safety studies as part of postmarketing commitments or postmarketing requirements. To date, the primary approach to post-approval safety data collection and evaluation in pregnant women has been the prospective exposure registry. 2 Prospective exposure registries are observational studies in which pregnant women exposed to a specified medication are enrolled for the purpose of actively collecting information about the exposure and specified associated outcomes. 1 These registries are intended to generate robust safety data that can contribute to understanding of risk-benefit of medications and guide clinical practice as it relates to use of medications in pregnancy. However, challenges to effective implementation of pregnancy exposure registries including difficulties in recruiting exposed patients, lack of adequate power to assess specific birth defects, and lack of adequate internal comparators have resulted in such registries failing to deliver robust information after many years of resource-intensive engagement. 3, 4 Not surprisingly, there is a need for complementary and alternative methods of assessing medication exposure in pregnancy, particularly observational studies using existing electronic administrative health care databases. 4, 5 With the expansion and evolution of health and medical records systems over the past 2 decades, it may now be possible for well-designed, pregnancy safety studies using existing databases to provide timely and high-quality data. For some indications, large cohorts of exposed pregnant women and adequate internal comparator(s) can be assembled for robust assessment.
Because of the potential methodological challenges inherent in retrospective electronic database studies, it is uncertain whether pregnancy safety information from such studies will provide reliable safety information as compared with that from prospective pregnancy registries. 6 Triptans are used to treat migraine, a neurological disease characterized by recurrent headache attacks of moderate to severe pain, with associated symptoms such as nausea/vomiting and aggravation of pain with physical activity. Around 75% of migraine patients are women, and the prevalence of migraine is the highest for ages 20 to 50 years, when women are of reproductive age. 7 Pharmacologic treatment of migraine during pregnancy is typically focused on acute medications, and sporadic use of triptans after the first trimester may be considered. Triptan exposure in pregnant migraine patients therefore offers a good example to examine whether assessment of safety using existing databases can provide findings comparable to those from a prospective pregnancy registry. In this analysis, we sought to assess outcomes associated with exposure of 3 triptan products in pregnancy using an existing health care database and compare the key findings with that of a previously completed pregnancy exposure registry. 8 2 | METHODS
| Overview
In this analysis, we assembled cohorts of pregnant women with migraine exposed to 1 of 3 triptans during pregnancy using an insurance administrative claims database and assessed pregnancy outcomes and proportion of major birth defects among live-born infants linkable to their birth mothers. The findings of this retrospective analysis using an existing database (hereafter referred to as the "claims analysis") were then compared with results reported for the final analysis of a completed 16-year, international, prospective pregnancy registry designed to evaluate the risk of major birth defects in women with migraine exposed to any one of 3 triptans during pregnancy.
The sumatriptan, naratriptan, and sumatriptan/naproxen pregnancy registry (hereafter referred to as the "registry") enrolled 904 pregnant women (between January 1996 and September 2012), and the final results were published in July/August of 2014. 8 Of the exposed pregnant women in the registry, 673 pregnancies and 680 pregnancy exposures were evaluable, with an overall loss to follow-up rate of 25.5%.The detailed methodology for the registry has been previously published. 8 The description of the methodological approach for the claims analysis follows.
| Data source and study cohorts
The study population for the claims analysis was drawn from adminis- 
KEY POINTS
• Prospective exposure registries, the traditional tool for post-approval safety ascertainment, are beset by numerous implementation challenges.
• There is a need for alternative and or complementary methodological approaches to evaluating the safety of medications during pregnancy.
• Utilizing existing electronic health records for pregnancy safety surveillance holds the prospect of both reducing the burden and increasing the quality of the information gleaned from these studies.
or after the migraine index date who were exposed to sumatriptan, naratriptan, or sumatriptan/naproxen sodium and had evidence of at least 1 of 4 pregnancy outcomes (livebirth, stillbirth, spontaneous abortion, and induced abortion). Pregnancy indicators were a combination of ICD-9-CM diagnosis codes, ICD-9-CM procedure codes, and CPT codes that indicate that a woman is receiving pregnancyrelated care and were based on algorithm that was developed by Hornbrook et al. 9 Using an hierarchical approach, this algorithm enables the identification of pregnancy events and outcome dates for pregnancies ending in a livebirth or one of the non-livebirth outcomes.
The pregnancy start date or date of conception is defined as the date of the last menstrual period, which is estimated by subtracting gestation age from the outcome date (ie, delivery date for livebirths and event date for non-livebirth outcomes). For pregnancies resulting in livebirth deliveries, gestational age was estimated using a validated algorithm. 10 This algorithm uses diagnosis codes for preterm and postterm births to estimate completed days of gestation. Gestation age for deliveries without an ICD-9-CM diagnosis code for preterm or postterm birth was assumed to be 273 days. Gestational age for pregnancies resulting in non-livebirth outcomes (stillbirths, spontaneous abortions, and induced abortions) was estimated using a published algorithm based on codes for certain pre-natal screening procedures.
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This algorithm is hierarchical, and it assigns completed weeks of gestation based on the presence of codes for at least one of common prenatal procedures including nuchal screen, triple screen, group B strep culture and ultrasound (fetal survey), rubella antibody, and hepatitis B surface antigen. Filled prescriptions of sumatriptan, naratriptan, and sumatriptan/naproxen sodium during the pregnancy episode were identified by National Drug Codes using pharmacy dispensing claims.
Mothers and infants were linked for completed pregnancies resulting in livebirth deliveries using their insurance ID, information on delivery-related claims date, infant birth year, and infants' first enrollment date. Linked infants were required to have 12-month continuous insurance enrolment beginning from the delivery date. Major birth defects in linked infants were grouped into categories according to organ system and ascertained during the first 12 months of life using ICD-9-CM diagnosis codes. 12 
| Statistical analyses
Characteristics of the pregnant women included in the study cohort for the claims analysis were described using means and proportions for continuous and categorical variables, respectively. The proportion of pregnancies resulting in livebirths, stillbirths, spontaneous abortions, and induced abortions were determined separately for pregnancies exposed to sumatriptan, naratriptan, and sumatriptan/naproxen sodium overall and stratified by earliest trimester of exposure. Among live-born infants linked to birth mothers, the frequency of major birth defects was determined overall and stratified by earliest trimester of exposure to sumatriptan, naratriptan, and sumatriptan/naproxen sodium.
The findings of the claims analysis were then compared with the results of the final analysis of the registry.
| RESULTS
In claims analysis using the Marketscan database, 5120 pregnancies among 4797 distinct women were included in the study cohorts ( Figure 1 ). About 4519 pregnancies were exposed to sumatriptan, 230 were exposed to naratriptan, and 371 were exposed to sumatriptan/naproxen sodium. The majority of exposed pregnancies had triptan dispensed in the first trimester. In contrast, the number of exposed pregnancies included in the final analysis of the registry was 617 for sumatriptan, 57 for naratriptan, and 6 for sumatriptan/ naproxen sodium, and the majority of exposed pregnancies also had triptan exposure during the first trimester ( Table 1 ). As shown in Table 2 , the majority of pregnant women in the claims analysis were aged 30 to 39 (59.3% of the sumatriptan-exposed cohort, 62.2% of the naratriptan-exposed cohort, and 63.9% of the sumatriptan/ naproxen sodium). During the 12-month period prior to the pregnancy episode, 25.7% of sumatriptan-exposed women had dispensing of nonsteroidal anti-inflammatory agents while 49.2% had dispensing of opioids. The proportions of nonsteroidal anti-inflammatory agents and opioids dispensed among pregnant women exposed to naratriptan and sumatriptan/naproxen sodium were similar. Prepregnancy maternal medication use and comorbid conditions were not reported in the final results from the registry.
Among 3496 pregnancy outcomes exposed to sumatriptan in the first trimester in the claims analysis, 5.0% were elective abortions, 18.0% were spontaneous abortions, 0.4% were stillbirths, and 77.7% were livebirth deliveries ( Table 3 ). The proportion of major birth defects in this cohort was 4.0%, which is exactly the same as the proportion of major birth defects reported for first-semester sumatriptan exposures in the registry. The proportion of outcomes that were elective abortions, spontaneous abortions, and livebirths for first-trimester naratriptan exposures in the claims analysis were 3.7%, 17.4%, and 78.9%, respectively. There were no recorded stillbirths or major birth defects for first-trimester naratriptan exposures in the claims analysis. Similarly, the proportion of outcomes that were elective abortions, spontaneous abortions, and livebirths for first-trimester naratriptan exposures in the registry were 1.9%, 9.6%, and 88.5%, respectively, and similar to the claims analysis, there were no recorded stillbirths. For the 296 first-trimester sumatriptan/naproxen sodium exposures in the claims analysis, 3.7% of outcomes were elective abortions, 18.9% were spontaneous abortions, 1.4% were stillbirths, and 76.0% were livebirths. The number of first-trimester sumatriptan/naproxen sodium exposures in the prospective registry analysis was too small (N = 5) to afford a meaningful comparison of outcomes.
The number of second or third trimester-exposed pregnancies is shown in Table 4 . About 940 sumatriptan-exposed, 35 naratriptanexposed and 68 sumatriptan/naproxen-exposed pregnancy outcomes were included in the retrospective claims analysis while the corresponding numbers for the pregnancy exposure registry analysis were 96 for sumatriptan, 5 for naratriptan, and 1 for sumatriptan/naproxen.
There were very few non-livebirth outcomes in both the claims analysis and registry. For pregnancies exposed to sumatriptan during the second or third trimester, the proportion of major birth defects among linked infants was 3.9% in the claims analysis and 3.1% in the registry.
| DISCUSSION
We aimed to estimate frequencies of major birth defects and pregnancy outcomes among pregnant women with migraine exposed to sumatriptan, naratriptan, or sumatriptan/naproxen sodium using a retrospective electronic health care database and to informally compare the findings with those reported for a completed 16-year prospective pregnancy registry. For the analysis using the retrospective claims database, 5120 exposed pregnancies were analyzed in comparison with 670 exposed pregnancies in the registry. Overall, there was The consistency observed between the key findings of the retrospective claims analysis and the registry regarding pregnancy outcomes in the setting of sumatriptan exposure supports the feasibility of retrospective observational study approaches in evaluating postapproval safety of triptan exposure in pregnancy. In addition, the findings of this study show that for some medications and disease indications, an observational cohort study using existing data may offer a viable alternative to prospective pregnancy registries in meeting the objectives of a postmarketing pregnancy safety surveillance. Not surprisingly, regulators have recently shown an openness to consider alternatives to the classic prospective pregnancy exposure registry in evaluating risks associated with exposure of medications during pregnancy. 13, 14 Overall, the frequency of abortions among triptan-exposed pregnant women were higher in the claims analysis than in the registry, and this is possibly because of a biased self-selection of subjects into the registry and under-reporting of these adverse pregnancy outcomes in the registry. 15 One strength of using administrative databases in evaluating pregnancy outcomes includes the possibility of accruing large numbers of exposures and pregnancy outcomes, particularly when multiple databases are combined. A recent review of 34 pregnancy registries reported a median enrolment of 36 exposed pregnancies. 16 In this study, the number of pregnancy exposures identified in one US database was over 7-fold that evaluable in the registry (which recruited between claims and chart review, and less robust for non-livebirth outcomes. 9 While valid determination of gestational age is essential for assigning trimester of medication exposure, for abortions and stillbirths, ascertainment of gestational age is very challenging. In the original validation study of the algorithm used to assign gestational age for non-livebirth outcomes in the present claims analysis, about 20% of pregnancies resulting in non-livebirth outcomes had none of the procedures that were used in the algorithm. 11 However, any misclassification arising from imperfect ascertainment of gestational age is likely nondifferential across the 3 exposure cohorts and poses minimal bias to our study findings. The generation of mother-infant pairs is dependent on the infant being covered under the same insurer as the mother, and mother-infant linkage algorithm used in this study linked 75.3% of live-born infants to their mothers. We have no reason to suspect differential linkage across pregnancy outcomes-as such we expect that incomplete linkage between mothers and infants is not likely to bias our study results. Denominators differ from the number of live-born infants because included infants were those (1) linkable to birth mothers and (2) had 12-month continuous insurance enrolment. Risk of major birth defects was calculated as number of infants with birth defects divided by the number of linkable livebirths with 12-month continuous insurance enrolment.
d The risk of major birth defects was calculated as the number of pregnancy outcomes with major birth defects divided by the sum of the number of livebirths without defects and the number of pregnancy outcomes with major birth defects. Denominators differ from the number of live-born infants because included infants were those (1) linkable to birth mothers and (2) had 12-month continuous insurance enrolment. Risk of major birth defects was calculated as number of infants with birth defects divided by the number of linkable livebirths with 12-month continuous insurance enrolment.
d The risk of major birth defects was calculated as the number of pregnancy outcomes with major birth defects divided by the sum of the number of livebirths without defects and the number of pregnancy outcomes with major birth defects.
without these birth defects. In the registry study, birth defects were ascertained in livebirths, stillbirths, and induced abortions, while in the database study, we are only able to ascertain birth defects in live-born infants. However, the numbers of major birth defects found in stillbirths and induced abortion in the registry were very small.
In conclusion, the findings of this study show that a sizable cohort of pregnant women exposed to medications of interest can be assembled using existing electronic health care databases. Our findings of high agreement between the results of a retrospective analysis using an existing database and a prospective pregnancy registry for the frequency of major birth defects in triptan-exposed pregnancies reinforce the utility of using existing databases for post-approval safety assessment of pregnancy exposures.
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